Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Hematopoietic stem cell transplantation for multiple sclerosis: finding equipoise.

R K Burt1, T Kozak

  • 1Northwestern University Medical Center, 320 East Superior, Searle 3-489 Chicago, IL 60611, USA. rburt@nwu.edu

Bone Marrow Transplantation
|August 22, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Treatment outcomes of Hodgkin lymphoma in the Czech Republic.

Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti·2026
Same author

The Efficacy and Toxicity of CNS Prophylaxis in Diffuse Large B-Cell Lymphoma (CLSG-CNS-01): A Randomized, Multicenter, Prospective Phase 3 Trial.

Hematological oncology·2026
Same author

OPTIMIZATION OF EXPERIMENTAL MODEL SYSTEMS FOR EVALUATING RECIPROCAL INFLUENCE OF BIFIDOBACTERIUM ANIMALIS AND HUMAN BREAST CANCER CELLS IN VITRO.

Experimental oncology·2024
Same author

Chemobrain in blood cancers: How chemotherapeutics interfere with the brain's structure and functionality, immune system, and metabolic functions.

Medicinal research reviews·2023
Same author

Assessment of biosafety and toxicity of hydrophilic gel for implantation in experimental in vitro and in vivo models.

BMC pharmacology & toxicology·2022
Same author

Autologous haematopoietic stem cell transplantation as a first-line disease-modifying therapy in patients with 'aggressive' multiple sclerosis.

Multiple sclerosis (Houndmills, Basingstoke, England)·2021

Hematopoietic stem cell transplantation shows promise for multiple sclerosis treatment. Patient selection is key, focusing on active inflammation and low disability, while avoiding neurotoxic conditioning agents for better outcomes.

Area of Science:

  • Neuroimmunology
  • Stem Cell Therapy
  • Neurology

Background:

  • Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease of the central nervous system.
  • Hematopoietic stem cell transplantation (HSCT) is an emerging therapeutic strategy for MS.
  • Understanding MS pathophysiology is crucial for optimizing HSCT protocols.

Purpose of the Study:

  • To review the expanding role of HSCT in multiple sclerosis treatment.
  • To outline critical considerations for designing successful HSCT clinical trials in MS.
  • To identify patient characteristics and treatment parameters that maximize efficacy and minimize risks.

Main Methods:

  • Review of current literature on HSCT for multiple sclerosis.
  • Analysis of patient selection criteria in existing clinical trials.

Related Experiment Videos

  • Evaluation of conditioning regimens and their potential impact on neural tissues.

    • Main Results:

    • HSCT is a rapidly expanding treatment modality for multiple sclerosis.
    • Successful HSCT requires careful patient selection, prioritizing active inflammatory disease and low disability.
    • Avoidance of conditioning agents detrimental to neural stem cells and axons is essential.

    Conclusions:

    • Hematopoietic stem cell transplantation offers a promising avenue for managing multiple sclerosis.
    • Optimizing trial design through precise patient stratification and judicious use of conditioning agents is paramount.
    • Further research is needed to refine HSCT protocols for long-term MS management.